Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.60 USD
+0.04 (0.72%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Alimera Sciences (ALIM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.67 | $6.00 | $5.50 | 1.98% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Alimera Sciences comes to $5.67. The forecasts range from a low of $5.50 to a high of $6.00. The average price target represents an increase of 1.98% from the last closing price of $5.56.
Analyst Price Targets (3 )
Broker Rating
Alimera Sciences currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, one is Strong Buy, representing 25% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.50 | 2.50 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | Alliance Global Partners | James Molloy | Strong Buy | Hold |
6/25/2024 | Maxim Group | Naz Rahman | Strong Buy | Hold |
6/25/2024 | H.C. Wainwright & Co. | Yi Chen | Strong Buy | Hold |
2/16/2024 | Craig-Hallum | Alex Nowak | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 4 |
Average Target Price | $5.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.03 |